Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Liabilities and Shareholders Equity: 2024

Historic Liabilities and Shareholders Equity for Kura Oncology (KURA) over the last 1 years, with Dec 2024 value amounting to $760.2 million.

  • Kura Oncology's Liabilities and Shareholders Equity rose 35.62% to $649.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year change of. This contributed to the annual value of $760.2 million for FY2024, which is N/A change from last year.
  • Kura Oncology's Liabilities and Shareholders Equity amounted to $760.2 million in FY2024.
  • Kura Oncology's Liabilities and Shareholders Equity's 5-year high stood at $760.2 million during FY2024, with a 5-year trough of $760.2 million in FY2024.
  • Its 1-year average for Liabilities and Shareholders Equity is $760.2 million, with a median of $760.2 million in 2024.